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Changes in Distribution of Dry 
Eye Disease by the New 2016 
Diagnostic Criteria from the Asia 
Dry Eye Society
Takenori Inomata  1,2, Tina Shiang3, Masao Iwagami4, Fumika Sakemi1, Keiichi Fujimoto1, 
Yuichi Okumura1, Mizu Ohno1 & Akira Murakami1
Dry eye disease (DED) is a disorder of the tear film. Here, we delineate the changes in distribution of 
DED after diagnostic criteria changes from the 2006 Japanese Diagnostic Criteria to the 2016 Asia Dry 
Eye Society criteria. We included 250 right eyes of 250 patients and all patients completed ophthalmic 
assessments for DED. The 2006 criteria classified patients into definite DED, probable DED, and non-
DED based on subjective symptoms, tear function, and/or vital staining. The 2016 criteria eliminated 
probable DED and classified patients into definite DED or non-DED based on subjective symptoms and 
decreased tear break-up time. We examined how probable DED patients were reclassified by the 2016 
criteria. By the 2006 criteria, 38.8% (97/250) of patients had definite DED, 35.6% (89/250) had probable 
DED, and 25.6% (64/250) had non-DED. By the 2016 criteria, 66.8% (167/250) had definite DED and 
31.2% (83/250) had non-DED. Among patients with probable DED using the 2006 criteria, 79.8% (71/89) 
were reclassified as definite DED and 20.2% (18/89) were reclassified as non-DED using the 2016 criteria. 
Our data revealed that prevalence of definite DED increased because most probable DED patients were 
reclassified as definite DED after changes in the diagnostic criteria.
Dry eye disease (DED) is a disorder of the tear film characterized by tear deficiency, excessive tear evapora-
tion and unstable tear film, causing a variety of symptoms and/or visual impairments, potentially accompanied 
by ocular surface damage1,2. Our understanding of DED has improved dramatically over the last 20 years with 
advancements in research. However, due to the disease’s complexity and unclear etiology, diagnostic criteria for 
DED are still not completely standardized worldwide.
Previously, DED was diagnosed by the 2006 Japanese Diagnostic Criteria for DED based on three assessments: 
subjective symptoms, tear function using either tear film break-up time (TBUT) ≤5 seconds or Schirmer test I 
(≤5 mm/5 min), and vital staining3. The 2006 criteria diagnosed definite DED with three positive items, proba-
ble DED with two positive items and non-DED with one or no positive items. In 2016, the Asia Cornea Society 
(ADES)4 and the Dry Eye Society Japan implemented new diagnostic criteria for DED that enabled diagnosis with 
only two positive items, namely subjective symptoms and decreased TBUT (≤5 seconds)2.
According to the 2016 criteria, probable DED is redistributed to definite DED or non-DED, but no clinical 
studies have investigated these changes to date. DED is the most common eye disease, affecting more than one 
billion people in the world5. Many people remain undiagnosed and experience a decreased quality of life (and 
decreased quality of vision)6,7. In addition, DED is increasing due to aging8, VDT (visual display terminals) syn-
drome accompanying smartphone and electronics use9, hormonal changes10, and stressful social environments11. 
Thus, it is necessary to clarify the change in the distribution of DED based on the 2016 diagnostic criteria to 
proactively recognize and identify appropriate interventions.
We aim to delineate the changes in the distribution of DED among patients, as defined by the 2006 criteria 
compared to the 2016 criteria.
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Results
The Characteristics of the Participants. We enrolled 250 patients (250 right eyes assessed) in this study 
(Table 1). All subjects completed the examination and were eligible for analysis. The average age was 61 ± 14 years 
old and 76.8% of the patients were women. According to the 2006 criteria, age was significantly older in non-DED 
patients compared to definite DED patients, best-corrected visual acuity (BCVA) was significantly better in defi-
nite DED patients compared to non-DED patients. More women had definite DED (88.7%) and probable DED 
(78.7%) compared to non-DED (56.3%). Positive subjective symptom rates (definite DED: 100%, probable DED: 
87.6%, non-DED: 7.8%), the Dry Eye-Related Quality-of-Life Score (DEQS)12 and corneal fluorescein staining 
(CFS) scores were significantly higher in definite DED and/or probable DED patients compared to non-DED 
patients. Conversely, TBUT and Schirmer test I were significantly lower in definite DED and/or probable DED 
patients compared to non-DED patients. Similar trends were observed in patients classified by the 2016 criteria. 
Age was significantly older in non-DED patients compared to definite DED patients, BCVA was significantly better 
in definite DED patients compared to non-DED patients. Positive subjective symptom rates, DEQS and CFS 
scores in definite DED patients were significantly higher compared to non-DED patients. TBUT in definite DED 
patients was significantly lower compared to non-DED patients. Schirmer test I was not significantly different 
between definite DED and non-DED patients.
The changes in distribution of DED subgroups per the 2006 and 2016 criteria. Table 2 shows 
the changes in the distribution of DED subgroups between the 2006 and 2016 criteria. According to the 2006 
criteria, the population distribution of DED is definite DED (38.8%, 97/250), probable DED (35.6%, 89/250), and 
non-DED (25.6%, 64/250); and according to the 2016 criteria, the distribution is definite DED (66.8%, 167/250) 
and non-DED (31.2%, 78/250). The majority of definite DED patients (99.0%, 96/97) and all of the non-DED 
patients (100.0%, 64/64) as defined by the 2006 criteria remained in those same categories using the 2016 criteria. 
Of note, the majority of probable DED patients were redistributed primarily to definite DED (79.8%, 71/89) and 
few to non-DED (20.2%, 18/89) under the 2016 criteria. Table 3 shows the classification of the probable DED 
group by clinical examinations based on the 2006 criteria and demonstrates how they were classified under the 
2016 criteria. In patients with probable DED per the 2006 criteria, the groups positive for subjective symptoms & 
TBUT positive (42.7%, 38/89) and subjective symptoms & TBUT & Schirmer test I (37.1%, 33/89) were reclassi-
fied as definite DED using the 2016 criteria. All other groups were reclassified as non-DED.
Subgroup analyses by age and sex. Figure 1A shows a 33.0% increase in the patients classified as definite 
DED after the transition from the 2006 to 2016 criteria. By sex and age, the percentage changes in the patients 
having definite DED were 4.9% increase in men, 4.9% decrease in women, 9.1% decrease in patients <65 years 
Criteria 2006 Criteria 2016 Criteria
Classification Non-DED Probable DED Definite DED
p value
Non-DED Definite DED
p value
Total
Characteristics ± SD n = 64 n = 89 n = 97 n = 83 n = 167 N = 250
Age, y 65.0 ± 14.1 63.3 ± 13.5 57.4 ± 12.7 **0.001 66.6 ± 13.0 58.2 ± 12.3 **0.003 61.4 ± 14.3
Female, n (%) 36 (56.3) 70 (78.7) 86 (88.7) ***<0.001 52 (62.6) 140 (83.8) **0.009 192 (76.8)
BCVA, LogMAR 0.1 ± 0.2 0.0 ± 0.2 0.0 ± 0.1 *0.03 0.1 ± 0.2 0.0 ± 0.1 **0.002 0.0 ± 0.2
IOP (mmHg) 13.7 ± 2.6 13.9 ± 3.1 13.8 ± 3.0 0.785 13.6 ± 2.7 13.8 ± 3.1 0.132 12.8 ± 2.9
Subjective symptom, 
yes (%) 5 (7.8) 78 (87.6) 97 (100.0) ***<0.001 13 (15.7) 167 (100.0) ***<0.001 180 (72.0)
DEQS score (95%CI) 11.5 ± 12.1 (3.0) 39.3 ± 26.0 (5.4) 35.7 ± 23.1 (4.6) ***<0.001 16.3 ± 21.0 (4.5) 36.4 ± 22.2 (3.4) ***<0.001 38.1 ± 23.8 (3.0)
TBUT, sec (95%CI) 4.9 ± 3.1 (0.8) 2.7 ± 1.9 (0.4) 1.6 ± 1.3 (0.3) ***<0.001 4.8 ± 3.1 (0.7) 1.8 ± 1.3 (0.2) ***<0.001 1.9 ± 2.4 (0.3)
CFS score (95%CI) 0.6 ± 0.8 (0.2) 1.5 ± 1.4 (0.3) 4.8 ± 1.9 (0.4) ***<0.001 1.1 ± 1.5 (0.3) 4.1 ± 2.5 (0.4) ***<0.001 4.1 ± 2.2 (0.3)
Schirmer I, mm 
(95%CI) 8.2 ± 6.3 (1.5) 7.2 ± 7.3 (1.5) 4.5 ± 5.5 (1.1) *0.012 8.4 ± 6.5 (1.4) 4.5 ± 5.9 (0.9) 0.083 4.4 ± 6.6 (0.8)
Table 1. The characteristics of study patients. P values were determined with the Student’s t-tests and one-
way ANOVA for continuous variables and chi-square test for categorical variables. 95% CI; 95% confidence 
intervals, DED; dry eye disease, BCVA; best corrected visual acuity, IOP; intraocular pressure, DEQS; the Dry 
Eye Related Quality Score, TBUT; tear film break-up time, CFS; corneal fluorescein staining.
Criteria
2006 Criteria
Classification Definite DED Probable DED Non-DED Total
2016 Criteria
Definite DED 96 (99.0) 71 (79.8) 0 (0) 167 (66.8)
Non-DED 1 (1.0) 18 (20.2) 64 (100) 78 (31.2)
Total 97 (100) 89 (100) 64 (100) 250 (100)
Table 2. Changes in distribution of patients with dry eye disease between the 2006 and 2016 criteria. Data are 
presented as the number of patients in each DED subgroup and the percentage of patients in each subgroup 
of the 2006 criteria that were reclassified into the definite DED and non-DED groups as defined by the 2016 
criteria. DED; dry eye disease.
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old and 9.1% increase in patients >65 years old. We also examined the percentage of patients previously classified 
as probable DED that were reclassified as definite DED under the 2016 criteria (Fig. 2B): 79.8% in total, 89.5% 
in men, 77.1% in women, 86.5% in patients <65 years old and 75.0% in patients ≥ 65 years old. Patients <65 
years old was primarily reclassified from probable DED to definite DED as compared to patients ≥ 65 years old 
(p < 0.032).
Additional analyses. Figure 2 compares the results of the Schirmer test I and TBUT among patients with 
definite DED between the 2006 and 2016 criteria. In the 2006 criteria, 70.1% of definite DED patients were posi-
tive for both TBUT and the Schirmer test I, and 28.9% were positive for only TBUT (Fig. 2A). In the 2016 criteria, 
61.7% of definite DED patients were positive for both TBUT and the Schirmer test I, and 38.3% were positive for 
only TBUT.
Discussion
The diagnostic criteria for DED were revised by ADES and Dry Eye Society Japan in 20162 and represented a 
standardization of DED diagnosis in Asia. With this revision, we can diagnose DED using only two items: positive 
subjective symptoms and decreased TBUT. Vital staining was removed from the diagnostic criteria, indicating a 
shift in emphasis to TBUT as a core measure of the tear film in the clinical diagnosis of DED.
From this study, we found that definite DED and non-DED patients diagnosed according to the 2006 criteria 
were similarly diagnosed using the 2016 criteria (Table 2). More importantly, among the probable DED patients, 
79.8% were reclassified as definite DED and 20.2% were reclassified as non-DED (Table 2) under the 2016 criteria, 
resulting in a general increase in the population diagnosed with definite DED (Fig. 1A).
In our study, we found that most patients with probable DED, most of which were reclassified as definite DED 
under the 2016 criteria, were short BUT-type DED (Table 3). Short BUT-type DED is defined as short TBUT 
2006 Criteria 2016 Criteria
Clinical examination Positive item (%) Classification
SS & CFS 3 (3.4) Non-DED
SS & TBUT 38 (42.7) Definite DED
SS & Schirmer 4 (4.5) Non-DED
SS & TBUT & Schirmer 33 (37.1) Definite DED
CFS & BUT 6 (6.7) Non-DED
CFS & Schirmer 0 (0) Non-DED
CFS & TBUT & Schirmer 5 (5.6) Non-DED
Total 89 (100)
Table 3. Classification of the Probable DED group using the 2006 vs 2016 criteria. Data are presented as the 
percentage of patients in the probable DED subgroups categorized by clinical examination using the 2006 
criteria. SS; subjective symptoms, CFS; corneal fluorescence staining, TBUT; tear break-up time, Schirmer; 
Schirmer test I, DED; dry eye disease.
Figure 1. The percentage changes in patients classified as definite DED under the 2016 criteria from the 2006 
criteria. (A) Changed distribution of definite DED between 2006 and 2016 criteria by age and sex. More men 
and patients > 65 years old had definite DED by the 2016 criteria. (B) Change distribution of probable DED to 
definite DED between the 2006 and 2016 criteria. 79.8% of probable DED patients were reclassified as definite 
DED according to the 2016 criteria. In the subgroup analysis, probable DED patients who were < 65 years old 
were often reclassified as definite DED. Data are considered statistically significant at *p < 0.05. Chi-square test 
was used to compare categorical variables.
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(≤5 seconds) accompanied by subjective symptoms without tear secretion deficiency or keratoconjunctival epi-
thelium abnormality13. Previous studies reported that short BUT-type DED causes as much ocular discomfort 
and visual dysfunction as classical DED13–16 and requires treatment. Current studies suggest Tear Film Oriented 
Therapy (TFOT)2, focused on stabilizing the tear film layer by selectively supplementing the deficient component 
layer(s) of the tear film, as a possible treatment for short BUT-type DED2. Table 3 also shows that the new defini-
tion includes some false negatives such as patients with subjective symptoms and low Schirmer values or patients 
with positive CFS with either low TBUT and or Schirmer values, which may represent patients in the early stages 
of DED not diagnosed by the new diagnostic criteria.
Kerato-conjunctival vital staining (CFS) was excluded from the 2016 diagnostic criteria for DED because of 
the finding that most DED is short BUT-type DED, which occurs without any keratoconjunctival epithelium 
abnormality13–16. However, it remains an important test since the corneal epithelium is an important barrier 
mechanism against infection17 and our study revealed that 74.9% of definite DED (125/167) has positive CFS 
(≥3). Despite its exclusion from the 2016 diagnostic criteria, kerato-conjunctival vital staining is simple, con-
venient and useful in accurately assessing DED severity, which is critical for selecting appropriate interventions 
accordingly. Kerato-conjunctival vital staining remains our best test for assessing DED severity and definitively 
confirming corneal epithelial disorder and thus should continue to be performed for this purpose, even though 
CFS was excluded from the 2016 diagnostic criteria.
Although the Schirmer test I has been widely used in the past to evaluate tear secretion volume, it was 
excluded in the 2016 criteria due to the low reproducibility and sensitivity16. In this study, 28.9% of patients with 
definite DED by the 2006 criteria had normal tear volume according to the Schirmer test I (Fig. 2A). A previous 
study on office workers showed that 79.9% of them had normal tear volume by the Schirmer test I16. Here we 
clearly showed that most definite DED patients shared features of short BUT and tear deficiency (Fig. 2, 70.1% 
according to 2006, 61.7% according to 2016 criteria). A previous study showed that tear deficient DED had less 
subjective symptoms, but with greater clinical severity18–20, indicating that corneal paresthesia in DED caused the 
divergence between subjective symptoms and clinical signs. Unfortunately, it is difficult to detect tear deficient 
DED with the new diagnostic changes set forth by the 2016 criteria.
In the 2016 revision, the significance of subjective symptoms increased. Although the majority of DED 
patients have some correlation between subjective symptoms and clinical signs of DED, recent studies have 
reported cases of discordance between clinical signs of DED and subjective symptoms21–23. Reduction of corneal 
sensation in severe or chronic DED20, and the presence of hyperalgesia in early or mild DED24 can account for 
the discordance. Furthermore, since aging is a risk factor for dry eyes, deterioration of corneal perception due 
to aging25 causes discordance of subjective symptoms and clinical symptoms in the elderly. Therefore, the 2016 
diagnostic criteria may not correctly diagnose definite DED when subjective symptoms and clinical signs are 
discordant.
Sex26,27 and age28 are important risk factors for DED and women are more frequently and severely affected 
than men29. However, the 2016 criteria may have revealed another at-risk population, men below 65 years old. 
Previously, this may have been overlooked because of the scarcity of corneal epitheliopathy in this population29. 
In our study, probable DED patients who were <65 years old were often reclassified as definite DED (Fig. 1B). 
Exclusion of corneal epitheliopathy from the 2016 diagnostic criteria resulting in the redistribution of DED 
patient classifications perhaps have made the presence of DED in men below 65 years old more apparent.
Sjogren’s syndrome also includes symptoms of dry eyes30. Its etiology for DED is characterized by exocrine 
gland inflammation, goblet cell loss and altered glycocalyx mucins, resulting in tear film instability and tear 
deficiency31,32. Currently, Sjogren’s syndrome is diagnosed using Schirmer test I and vital staining in Japan30. 
However, since the 2016 criteria removed the Schirmer test I and kerato-conjunctival vital staining from the 
diagnostic criteria, the emphasis of DED has shifted from tear deficiency to tear film instability, making it difficult 
to distinguish between these two subtypes of DED. However, in the subgroup analysis of Sjogren’s syndrome 
Figure 2. Changes in the scatter plot of Schirmer test I values and TBUT among four subtypes of patients with 
definite DED per the 2006 and 2016 criteria. Figures show the scatter plot of Schirmer test I results and TBUT 
by the (A) 2006 criteria and the (B) 2016 criteria. TBUT; tear break-up time.
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(Supplemental Table 1E), most of them had definite DED in the 2006 criteria (78.0%, 46/59) and were almost all 
reallocated to definite DED in the 2016 criteria (91.5%, 54/59). Our data clearly support that Sjogren’s syndrome 
shares features of tear film instability and tear deficiency, and the 2016 criteria included patients with DED caused 
by Sjogren’s syndrome even though it has excluded the Schirmer test I.
This study has a few limitations. There were a high proportion of DED patients in our study, likely due to some 
selection bias in choosing participants from a university hospital5,33. In addition, among patients with non-DED, 
age was significantly older and BCVA was significantly lower compared to patients with definite DED because 
many patients with non-DED may come for cataract examinations. This study also does not exclude patients 
with systemic diseases and systemic treatments. Since the examination was designed to investigate the influence 
of the new diagnostic criteria, rose bengal stain scores, tear osmolality and corneal sensations were not applied 
to all subjects. Despite these limitations, our data revealed the changes in the distribution of DED by the 2016 
criteria, which eliminated the probable DED category, now a remnant of the 2006 criteria. Another limitation is 
our study did not assess meibomian gland dysfunction (MGD), which is due to insufficient production of mei-
bum. However, it is fair to assume that the DED criteria has already included the MGD population because MGD 
shares clinical features of aqueous-deficient DED, including tear film instability and potential ocular surface 
compromise34.
In summary, we identified a changed distribution of patients in DED subgroups using the 2016 criteria. 
Patients previously categorized as probable DED were mostly redistributed to definite DED under the 2016 crite-
ria. Patients categorized as definite DED and non-DED in the 2006 criteria corresponded to the respective groups 
in the 2016 criteria. Short BUT-type DED is not yet considered an independent disease category of DED globally, 
but the 2016 revision highlighted short BUT-type DED as a core concept. Specifically, tear film instability due 
to decreased TBUT, even without the presence of corneal epithelial damage, is an indispensable indicator in the 
diagnosis and treatment of DED.
We showed a change in population distribution of DED groups using the 2016 criteria. There was a significant 
increase in the number of patients with definite DED, primarily due to the reclassification of patients previously 
diagnosed as probable DED under the 2006 criteria to definite DED under the 2016 criteria. This expanded dis-
ease population emphasizes the critical importance of timely diagnosis and treatment of short BUT-type DED.
Participants and Methods
Study design and Participants. This cross-sectional observational study included 250 right eyes of 250 
patients recruited between November 2015 and April 2017 from Juntendo University Hospital, Department of 
Ophthalmology, Tokyo, Japan. Written informed consent was waived due to the retrospective observational study 
and this study was carried out by the opt-out method of our hospital website. The clinical study was conducted 
under Juntendo University Hospital, Independent Ethics Committee (Approval number, 15-185) and adhered to 
the tenets of the Declaration of Helsinki.
Exclusion Criteria. We excluded patients with a history of diabetes, uveitis, glaucoma, increased IOP, eye 
surgery, any corneal disease including herpetic keratitis, endothelial guttae and contact lens wear.
Dry Eye Disease Diagnosis and Classification. All patients had a complete ophthalmic evaluation 
including measurement of BCVA, IOP, subjective symptoms using the DEQS questionnaire12, TBUT, CFS for 
kerato-conjunctival vital staining and Schirmer test I for reflex tear production. We diagnosed definite DED, 
probable DED and non-DED using the 2006 criteria3, and definite DED and non-DED using the 2016 criteria2. 
The 2006 criteria diagnosed definite DED with three positive items, probable DED with two positive items and 
non-DED with one or no positive items. The 2016 criteria diagnosed definite DED with two positive items, spe-
cifically positive subjective symptoms and decreased TBUT (≤5 seconds).
Subjective Symptoms and Dry Eye-Related Quality Score (DEQS). Subjective symptoms were col-
lected by interviewing subjects with DED. The DEQS questionnaire was performed to assess the severity of dry 
eye-associated symptoms and the multifaceted effects of DED on the patients’ daily lives. The questionnaire used 
in this study has been evaluated for its internal validity and reliability for use in the Japanese population12. The 
score derived from this questionnaire is a subjective measurement of DED symptoms where 0 indicates the best 
score (no symptoms) and 100 indicates the worst score (maximal symptoms).
Clinical Assessments. TBUT and kerato-conjunctival vital staining (CFS) were assessed with fluorescein 
sodium (Fluores Ocular Examination Test Paper, Ayumi Pharmaceutical Co., Tokyo, Japan) staining. We per-
formed TBUT, kerato-conjunctival vital staining and subsequently Schirmer test I. To avoid the influence of 
TBUT and kerato-conjunctival vital staining on the Schirmer I test, we waited a minimum interval of 15 min 
between tests.
Tear Break-up Time (TBUT). TBUT is measured using a fluorescein dye according to the standard method2. 
To minimize the effect on tear volume and TBUT, a small quantity of dye was administered with a wetted fluores-
cein strip. After the dye was instilled, the subject was instructed to blink three times to ensure adequate mixing 
of the dye with the tears. The time interval between the last blink and the appearance of the first dark spot on the 
cornea was measured with a stopwatch. The mean value of the three measurements was used. The cutoff value of 
TBUT ≤5 seconds was used to diagnose DED2.
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Kerato-conjunctival Vital Staining (Cornea Fluorescence Staining; CFS). CFS was graded accord-
ing to the van Bijsterveld grading system35. Van Bijsterveld described a scoring system that divides the ocular 
surface into three zones: nasal bulbar conjunctiva, temporal bulbar conjunctiva, and cornea. Each zone was evalu-
ated on a scale of 0 to 3, with 0 indicating no staining and 3 indicating confluent staining. The maximum possible 
score is 9.
Schirmer test I. The Schirmer test I was performed without topical anesthesia, following all other examina-
tions. Schirmer’s test strips (Ayumi Pharmaceutical Co., Tokyo, Japan) were placed at the outer one-third of the 
temporal lower conjunctival fornix for 5 minutes. The strips were then removed, and the length of dampened filter 
paper (in mm) was recorded.
Statistical analyses. We examined the characteristics of the patients according to the DED classifications 
based on the 2006 and 2016 criteria. Student’s t test was used to compare continuous variables between two 
groups. One-way ANOVA with Bonferroni post hoc test was used to compare between three groups. Chi-square 
test was used to compare categorical variables. Data are presented as mean ± standard deviation (SD) or pro-
portion. We analyzed the distribution changes of DED in the population between the 2006 and 2016 criteria. In 
addition, we calculated the proportion changes of definite DED between the 2006 and 2016 criteria.
We performed a subgroup analysis of probable DED patients classified by the 2006 criteria and examined how 
those subgroups were reallocated using the 2016 criteria. In addition, we conducted subgroup analysis by age, sex 
and Sjogren’s syndrome. To assess the relationship between TBUT and Schirmer test I, we performed scatter plot 
analysis of definite DED patients between the 2006 and 2016 criteria.
The data and statistical analyses were conducted using STATA version 14 (Stata Corp, Texas). A p-value of 
<0.05 was considered statistically significant.
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